AMCP Market Insights: Managed care approaches to ESR1-mutated advanced breast cancer.

Bridget Flavin¹, Carol Tweed², Janna Evans³, Sara L Fleszar⁴, Gaurang Gandhi⁵, Kirollos S Hanna⁶, Ryan Haumschild⁷, Timothy O'Shea⁸, Terry Richardson⁹, Tina Valbh¹⁰, Denise Wolff¹¹

¹Connected Content, Ltd., Boulder, CO.

²Maryland Oncology Hematology, Annapolis.

³Blue Cross Blue Shield Texas, Houston.

⁴Optum Whole Health Solutions, Denver, CO.

⁵Prime Therapeutics/MagellanRx, Eagan, MN.

⁶Minnesota Oncology, Mayo Clinic School of Medicine, Minneapolis-St. Paul.

⁷Emory Healthcare and Winship Cancer Institute, Atlanta, GA.

⁸Horizon Blue Cross Blue Shield of New Jersey, Newark.

⁹Impact Education, LLC, Blue Bell, PA.

¹⁰PharmaKonnect, Tina's Warriors, Mount Dora, FL.

¹¹Denise & Co., LLC, Duluth, Minnesota.

PubMed DOI

Abstract

A mutation in the estrogen receptor alpha gene (ESR1m) following first-line treatment with endocrine therapy in hormone receptor-positive metastatic breast cancer occurs in nearly half of patients. Detection of this mutation prior to radiologic progression using circulating tumor DNA (ctDNA)-based monitoring is an emerging practice that may allow an early switch to a more effective therapy. To dis…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.